Chronic cough, defined as a cough persisting for more than eight weeks, presents a diagnostic and therapeutic challenge for clinicians. Despite its prevalence, the approach to chronic cough often lacks a systematic and comprehensive strategy, leading to delayed diagnosis and suboptimal management.
Initially, clinicians should differentiate between cough-variant asthma, gastroesophageal reflux disease, and upper airway cough syndrome, the three most common causes of chronic cough. A comprehensive medical history, physical examination, and judicious use of investigations like spirometry, chest radiographs, and upper gastrointestinal endoscopy can guide diagnosis. Additionally, the role of newer diagnostic modalities, such as impulse oscillometry and laryngeal sensory testing, is expanding.
Treatment should be etiology-specific and patient-centered. Empiric treatment trials can be considered when the diagnosis is uncertain. For cough-variant asthma, inhaled corticosteroids are the mainstay of treatment. Proton pump inhibitors are recommended for gastroesophageal reflux disease-associated cough, while antihistamines and nasal corticosteroids can be used for upper airway cough syndrome. Refractory cases may benefit from neuromodulatory agents like gabapentin and pregabalin.
Recent research has shed light on the phenomenon of cough hypersensitivity syndrome, a condition where cough receptors in the airway become hypersensitive, leading to chronic cough. This has opened new avenues for the development of novel therapeutic agents targeting the cough reflex pathway, such as P2X3 receptor antagonists.
In conclusion, a comprehensive and systematic approach to chronic cough is essential for accurate diagnosis and effective management. Emerging concepts and novel therapeutic agents promise to transform the landscape of chronic cough management in the future. Clinicians need to stay abreast of these developments to provide optimal care for patients with chronic cough.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation